Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant sintilimab before radical cystectomy for muscle-invasive bladder cancer
ChiCTR2000032730Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in bladder cancer and transitional cell carcinoma (TCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: pathological complete response rate. Started Jul 2019; status: recruiting.
02
Drugs
sintilimab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000032730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032730.